Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition

J.R. Vos, I.E. Fakkert, J.A. de Hullu, A.M. van Altena, A.S. Sie, H. Ouchene, R.W. Willems, I.D. Nagtegaal, M.C.J. Jongmans, A.R. Mensenkamp, G.H. Woldringh, J. Bulten, E.M. Leter, C.M. Kets, M. Simons, M.J.L. Ligtenberg, N. Hoogerbrugge, Roy Lalisang, OPA Working Group

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)161-169
Number of pages9
JournalJournal of the National Cancer Institute
Volume112
Issue number2
DOIs
Publication statusPublished - 1 Feb 2020

Keywords

  • breast
  • double-blind
  • germline
  • maintenance therapy
  • mutation carriers
  • platinum
  • risk
  • somatic mutations
  • survival
  • SURVIVAL
  • GERMLINE
  • MUTATION CARRIERS
  • PLATINUM
  • RISK
  • MAINTENANCE THERAPY
  • SOMATIC MUTATIONS
  • BREAST
  • DOUBLE-BLIND

Cite this